Stockscreener 앱 받기
0.271
5.64%
-0.0162
전일 마감가:
$0.2872
열려 있는:
$0.27
하루 거래량:
997.66K
Relative Volume:
0.09
시가총액:
$8.38M
수익:
$9.37M
순이익/손실:
$-8.45M
주가수익비율:
-0.3346
EPS:
-0.81
순현금흐름:
$-7.27M
1주 성능:
+9.27%
1개월 성능:
-3.21%
6개월 성능:
-70.22%
1년 성능:
-87.79%
1일 변동 폭
$0.255
$0.2799
1주일 범위
$0.237
$0.46
52주 변동 폭
$0.1639
$2.9893
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
명칭
Bioaffinity Technologies Inc
전화
210-698-5334
주소
3300 NACOGDOCHES ROAD, SAN ANTONIO
BIAF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.2716 | 8.38M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
419.40 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
200.48 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
542.17 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.26 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
162.66 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Bioaffinity Technologies Inc 주식(BIAF)의 최신 뉴스
bioAffinity Technologies (NASDAQ:BIAFW) Trading 2.1% Higher – What’s Next? - Defense World
bioAffinity Technologies Stock Price, Quotes and Forecasts | NASDAQ:BIAF - Benzinga
BIAF’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Kalkine : bioAffinity Technologies BIAF Nasdaq Composite - Kalkine Media
bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Large Growth in Short Interest - Defense World
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board - BioSpace
bioAffinity CEO Joins American Lung Association Texas Leadership Board | BIAFW Stock News - Stock Titan
Gordon Downie Named Chief Medical Officer at bioAffinity Technologies - Medical Product Outsourcing
BIAFbioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 - Revista ADVFN
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence - mx.advfn.com
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung - Yahoo Finance
Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Grows By 58.8% - Defense World
bioAffinity Receives Nasdaq Non-Compliance Notice - TipRanks
BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors - Insider Monkey
BioAffinity Technologies Announces New U.S. Patent For Novel Broad Spectrum Cancer Therapeutics - marketscreener.com
BIAF Gains New Patent for Innovative Cancer Treatment Method | B - GuruFocus
Revolutionary Cancer Treatment Patent: bioAffinity's New Therapy Kills Cancer Cells While Sparing Healthy Ones - Stock Titan
bioAffinity Technologies Enters Sales Agreement with WallachBeth - TipRanks
bioAffinity Technologies (NASDAQ:BIAF) Trading Down 3.1% – What’s Next? - Defense World
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline - MSN
bioAffinity Technologies names new chief medical officer By Investing.com - Investing.com South Africa
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer - citybiz
BioAffinity Technologies (BIAF) Appoints Gordon Downie as Chief Medical Officer | BIAF Stock News - GuruFocus
bioAffinity Technologies names new chief medical officer - Investing.com Australia
From Olympic Bronze to Cancer Breakthrough: bioAffinity Names Elite Physician as New CMO - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
bioAffinity Technologies Sets 2025 Annual Meeting Date - TipRanks
Earnings roundup: ‘Uncertain’ conditions weigh on companies’ bottom lines - San Antonio Express-News
bioAffinity Technologies Reports Strong Q1 2025 Growth - MSN
bioAffinity Technologies, Inc. SEC 10-Q Report - TradingView
bioAffinity Technologies Reports First Quarter 2025 Results - Business Wire
bioAffinity Technologies Completes $3.2M Public Offering - TipRanks
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering - The Malaysian Reserve
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer - Stock Titan
bioAffinity announces $3.25 million securities offering By Investing.com - Investing.com Nigeria
bioAffinity Technologies completes $3.25 million offering By Investing.com - Investing.com South Africa
BioAffinity Technologies Closes $3.25 Million Offering - marketscreener.com
bioAffinity Technologies (BIAF) Completes $3.25M Securities Offering | BIAF Stock News - GuruFocus
bioAffinity Technologies completes $3.25 million offering - Investing.com
bioAffinity Technologies Announces Closing of $3.25 Million Offering - Bluefield Daily Telegraph
bioAffinity Technologies Boosts Data Acquisition for CyPath Lung Test - Medical Product Outsourcing
BioAffinity Technologies announces pricing of $3.25M offering - Yahoo Finance
Crude Oil Rises Sharply; US Trade Deficit Widens In March - Benzinga
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering - Eastern Progress
The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies - NewsBreak: Local News & Alerts
Cancer Detection Biotech bioAffinity Secures Fresh $3.25M Funding: Key Details of Latest Stock Offering - Stock Titan
bioAffinity announces $3.25 million securities offering - Investing.com Australia
Dow Falls Over 250 Points; Marriott Posts Upbeat Earnings - Benzinga
Bioaffinity Technologies Inc (BIAF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.83%
2.47%
자본화:
|
볼륨(24시간):